<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[license agreement and merck Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/license+agreement+and+merck.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to license agreement and merck]]></description>
	<s:counts start="0" returned="20" found="40" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Hercules Technology Growth Capital Announces Successful Fund Raising Activities from Select Life Sciences Portfolio Companies Despite Challenging Economy]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_20090727/ai_n32368905]]></link>
		<description><![CDATA[       Novasys Medical and AVEO Pharmaceuticals secure additional equity        capital while Portola Pharmaceuticals enters into Worldwide License        Agreement with Merck & Co., Inc.       ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 27 Jul 2009 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/hercules+technology+growth+capital+inc..html"><![CDATA[Hercules Technology Growth Capital Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HTGC</category>
		<category domain="tickers">HTGC</category>
	</item>
	<item>
		<title><![CDATA[Life Science Looks to Big Pharma for Funding as Caution Still Reigns]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F143121-life-science-looks-to-big-pharma-for-funding-as-caution-still-reigns%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[The Burrill Report submits:  By MARIE DAGHLIAN Last week's flurry of public-share offerings must have been a blip on the radar screen, as most life sciences companies look to private investors for much needed cash. And while the number of PIPEs and venture-capital financings continues at a fairly good...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 15 Jun 2009 12:23:42 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/the+burrill+report.html"><![CDATA[The Burrill Report]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">DNA,MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck & Co., Inc. and Cardiome Pharma Corp. sign a collaboration and license agreement for the development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation.(INDUSTRIAL Briefs)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb6468/is_200905/ai_n31986737]]></link>
		<description><![CDATA[  Merck & Co., Inc. and Cardiome Pharma Corp. sign a  collaboration and license agreement for the development and  commercialization of vernakalant, an investigational candidate for the  treatment of atrial fibrillation. The agreement provides Merck with  exclusive global rights to the oral formulation of vernakalant...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 01 May 2009 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/cardiome+pharma+corp..html"><![CDATA[Cardiome Pharma Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">COM CRME</category>
		<category domain="tickers">COM CRME</category>
	</item>
	<item>
		<title><![CDATA[Merck & Co., Inc. and Cardiome Sign License Agreement for Vernakalant, an Investigational Drug for Treatment of Atrial Fibrillation]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_20090408/ai_n31522405]]></link>
		<description><![CDATA[       WHITEHOUSE STATION, N.J. & VANCOUVER -- Merck & Co., Inc. and Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM)        today announced a collaboration and license agreement for the        development...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 08 Apr 2009 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/cardiome+pharma+corp..html"><![CDATA[Cardiome Pharma Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">COM CRME</category>
		<category domain="tickers">COM CRME</category>
	</item>
	<item>
		<title><![CDATA[EMD Serono Snags US license for Tesamorelin From Theratechnologies]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F103241-emd-serono-snags-us-license-for-tesamorelin-from-theratechnologies%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits:   Theratechnologies and EMD Serono, US arm of Merck KGaA (MKGAY.PK), announced they have entered into a collaboration and licensing agreement for the exclusive commercialization rights to tesamorelin in the United States for the treatment of excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies retains all...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 31 Oct 2008 03:44:29 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/commercialization.html"><![CDATA[Commercialization]]></category>
		<category domain="http://resources.bnet.com/topic/serono+s.a..html"><![CDATA[Serono S.A.]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/tesamorelin.html"><![CDATA[Tesamorelin]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/theratechnologies.html"><![CDATA[Theratechnologies]]></category>
		<category domain="http://resources.bnet.com/topic/service+management.html"><![CDATA[Service Management]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
	</item>
	<item>
		<title><![CDATA[Celera Grants License to Merck & Co., Inc. for Cancer Targets]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_April_10/ai_n25147083]]></link>
		<description><![CDATA[ALAMEDA, Calif. -- Celera (NYSE:CRA), an Applera Corporation business, today announced a two year exclusive license agreement with Merck & Co., Inc. providing Merck with access to up to ten cancer targets for the development of RNA interference-RNAi based therapeutics. These therapeutic targets are over-expressed on the surface of several...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 10 Apr 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Addex Achieves First Milestone in Parkinson&#39;s Disease Collaboration with Merck & Co., Inc.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200802/ai_n24330505]]></link>
		<description><![CDATA[Allosteric   modulation company   Addex Pharmaceuticals (SWX: ADXN) announced today that the first preclinical milestone  has  been  achieved  in  a  recently  announced exclusive collaboration and license agreement with  Merck & Co., Inc. (through its affiliate Merck Sharp & Dohme...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 25 Feb 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/collaboration.html"><![CDATA[collaboration]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/parkinson.html"><![CDATA[Parkinson]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Addex Achieves First Milestone in Parkinson&#39;s Disease Collaboration With Merck & Co., Inc.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200802/ai_n24330511]]></link>
		<description><![CDATA[Allosteric modulation company Addex Pharmaceuticals (SWISS: ADXN) announced today that the first preclinical milestone has been achieved in a recently announced exclusive collaboration and license agreement with Merck & Co., Inc. (through its affiliate Merck Sharp & Dohme Research Ltd). The collaboration is focused on developing an emerging class of...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 25 Feb 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/collaboration.html"><![CDATA[collaboration]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/parkinson.html"><![CDATA[Parkinson]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Compugen Announces GPCR Ligand Discovery and License Option Agreement With Merck]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Jan_14/ai_n24229351]]></link>
		<description><![CDATA[TEL AVIV, Israel -- Compugen Ltd. (NASDAQ:CGEN) announced today a collaboration with Merck & Co., Inc., Whitehouse Station, New Jersey, targeted at predicting peptides likely to activate selected G-protein coupled receptors GPCRs and validating their agonistic activity. The agreement includes an option to Merck for exclusive worldwide licenses for such...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 14 Jan 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Addex and Merck & Co., Inc. Enter License Agreement to Develop a Drug Candidate for Schizophrenia]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200801/ai_n21177951]]></link>
		<description><![CDATA[Second Merck Deal Demonstrates the Value of Addex' Allosteric Modulator Platform ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 03 Jan 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/license+agreement.html"><![CDATA[license agreement]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Addex and Merck & Co., Inc. Enter License Agreement to Develop a Drug Candidate for Schizophrenia]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200801/ai_n21177952]]></link>
		<description><![CDATA[English Version PDF  http://hugin.info/138017/R/1179258/234710.pdf  French Version PDF  http://hugin.info/138017/R/1179258/234711.pdf  German Version PDF  http://hugin.info/138017/R/1179258/234712.pdf  ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 03 Jan 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/adobe+pdf.html"><![CDATA[Adobe PDF]]></category>
		<category domain="http://resources.bnet.com/topic/license+agreement.html"><![CDATA[license agreement]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Geron Receives Milestone Payment from Merck Triggered by IND Filing for Telomerase Cancer Vaccine Candidate]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Dec_12/ai_n27472580]]></link>
		<description><![CDATA[MENLO PARK, Calif. -- Geron Corporation (Nasdaq:GERN) announced today that Merck & Co, Inc. has filed an Investigational New Drug application ("IND") with the U.S. Food and Drug Administration ("FDA") for a cancer vaccine candidate that targets telomerase. Merck is developing the vaccine under a July, 2005 Research, Development and...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 12 Dec 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[ImClone Systems Inc. Q3 2007 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-232494.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  [Operator Instructions].  Your first question comes from May-Kin Ho of Goldman Sachs.  May-Kin Ho - Goldman Sachs  Hi. I guess, I wanted to ask question about really how your payment from Bristol would be recognized and how we should going forward project out...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 25 Oct 2007 22:32:15 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/imclone+systems+inc..html"><![CDATA[ImClone Systems Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">IMCL</category>
		<category domain="tickers">IMCL</category>
	</item>
	<item>
		<title><![CDATA[Applera Corporation F1Q08 (Qtr End 9/30/07) Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14046_23-232503.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  Thank you sir. [Operator&#8217;s instructions.]  One moment while we compile a list of questions. Our first question will come from the line of Ross Muken of Deutsche Bank, please proceed.  Ross Muken &#8211; Deutsche Bank  Good morning everyone.  Mark P. Stevenson &#8211;...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 25 Oct 2007 22:00:10 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/applera+corp..html"><![CDATA[Applera Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABI</category>
		<category domain="tickers">ABI</category>
	</item>
	<item>
		<title><![CDATA[MethylGene Regains Exclusive Rights to Beta-Lactamase Inhibitor Program from Merck.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5559/is_200708/ai_n22563427]]></link>
		<description><![CDATA[MONTREAL, QUEBEC, Aug 1, 2007 CCNMatthews via COMTEX --  MethylGene Inc. (TSX:MYG) announced that it has received notice today  that Merck intends to terminate the exclusive license and research  collaboration agreement, entered into by the companies   MONTREAL, QUEBEC, Aug 1, 2007 CCNMatthews via COMTEX --...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 01 Aug 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[MethylGene Regains Exclusive Rights to Beta-Lactamase Inhibitor Program from Merck]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200708/ai_n19428810]]></link>
		<description><![CDATA[MethylGene Inc. (TSX: MYG) announced that it has received notice today that Merck intends to terminate the exclusive license and research collaboration agreement, entered into by the companies on June 23, 2003, in accordance with its terms. Termination of the agreement will be effective 90 days from today. ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 01 Aug 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[SurModics and Merck Announce Entering an Ophthalmic License and Research Collaboration Agreement.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200706/ai_n19766676]]></link>
		<description><![CDATA[M2 PRESSWIRE-28 June 2007-Upward Momentum: SurModics and Merck  Announce Entering an Ophthalmic License and Research Collaboration  AgreementC1994-2007 M2 COMMUNICATIONS LTD    RDATE:28062007    Market Gainer is quickly emerging as the one stop shop for  international small-cap investors looking to stay a step ahead...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 28 Jun 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/investor.html"><![CDATA[investor]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/polymer.html"><![CDATA[polymer]]></category>
		<category domain="http://resources.bnet.com/topic/surmodics+inc..html"><![CDATA[SurModics Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SRDX</category>
		<category domain="tickers">MRK,NDAQ,SRDX</category>
	</item>
	<item>
		<title><![CDATA[SurModics and Merck Enter Ophthalmic License and Research Collaboration Agreement]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_June_27/ai_n27290602]]></link>
		<description><![CDATA[Includes Both I-vation[TM] TA and I-vation[TM] Platform for Merck Drugs]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 27 Jun 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Cubist Pharmaceuticals Licenses Rights for Development and Commercialization of CUBICIN in Japan to Merck & Co., Inc]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_March_22/ai_n27190583]]></link>
		<description><![CDATA[LEXINGTON, Mass. -- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has entered into a license agreement with Merck & Co., Inc. for the development and commercialization of CUBICIN[R] daptomycin for injection in Japan. Merck will develop and commercialize CUBICIN through its wholly-owned subsidiary, Banyu Pharmaceutical Co., Ltd. With...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 22 Mar 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Acumen Pharmaceuticals Announces Amended Agreement with Merck to Include Exclusive Diagnostic Rights]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Nov_27/ai_n16869278]]></link>
		<description><![CDATA[SOUTH SAN FRANCISCO, Calif. -- Acumen Pharmaceuticals, a leading pre-clinical biotech company working in Alzheimer's therapeutics, today announced that it has amended its existing license agreement with Merck & Co., Inc. to grant an exclusive license to research and develop amyloid-derived diffusible ligand ADDL directed diagnostic products.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 27 Nov 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
</channel>
</rss>
